Formosa Pharmaceuticals and AimMax Therapeutics announce NDA Submission to USFDA for APP13007
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
It is the first presbyopia-correcting lens implant for cataract surgery
Subscribe To Our Newsletter & Stay Updated